Ethics; Pharmacogenomics; Pre-Emptive Testing; Patient Care

4B - Ethical Challenges in Pre-Emptive PGx Testing
CME (AMA PRA Category 1 Credits™) 1.5; ACPE (UAN: 0853-9999-17-062-L01-P) 1.5; CEU (NSGC Category 1) 0.15; Attendance CEU 1.5

Tuesday, October 10
1:20 PM - 2:50 PM

As pharmacogenomic testing becomes more prevalent in our healthcare setting, enabled by lower costs and more clinical applications, mechanisms in medical systems and decision support tools are being constructed to allow wide scale pre-emptive pharmacogenomic testing. This session examines some of the ethical challenges and social concerns that this testing may unearth.

Learning Objectives:

Liewei Wang

Professor of Pharmacology Co-Director Mayo Pharmacogenomics Program
Mayo Clinic

Liewei Wang, MD, received her MD degree from FuDan University, Shanghai, China, followed by a PhD. degree from the Mayo Graduate School, with an emphasis on cancer biology and cancer pharmacology. Currently, she is a Professor of the Department of Molecular Pharmacology and Experimental Therapeutics at Mayo Clinic.

Dr. Wang has developed a research program with a focus on the use of high throughput genomic technology including array based and next generation sequencing methods, joined with a cell-based model system that consists of 300 lymphoblastoid cell lines, to study mechanisms of cancer biology and antineoplastic drug resistance, both chemotherapy and radiation therapy. In addition to her career-long involvement in pharmacogenomics, she also has extensive experience in functional genomics. She is involved in many clinical translational studies which help identify and understand biomarkers associated with clinical response to endocrine therapy and chemotherapy in breast cancer patients.

Dr. Wang is a member of several key programs at Mayo including: the Mayo-NIH Comprehensive Cancer Center (MCCC) and the Mayo Center for Individualized Medicine (CIM). She is also Co-Principal Investigator and the leader of the Functional Genomics Group for the Mayo-NIH Pharmacogenetics Research Network (PGRN) and the Co-Director for the Pharmacogenomics Program in the Mayo CIM.

Presentation(s):

Send Email for Liewei Wang

Richard R. Sharp

Director, Biomedical Ethics Research Program
Biomedical Ethics Research Program, Mayo Clinic

Richard Sharp, PhD, is Director of the Biomedical Ethics Program at Mayo Clinic. Prior to joining Mayo Clinic in July 2013, he was Director of Bioethics Research at Cleveland Clinic and Co-Director of the Center for Genetic Research Ethics and Law at Case Western Reserve University, one of six NIH Centers of Excellence in Ethics Research. Dr. Sharp has published widely on topics in biomedical ethics, including clinical ethics consultation, informed consent, financial conflicts of interest, and ethical tensions in patient advocacy. His current research is examining how patients and healthcare providers view new forms of personalized medicine and clinical interventions enabled by molecular diagnosis. Dr. Sharp frequently advises healthcare organizations on ethical issues and has served on advisory committees for the National Institutes of Health, Institute of Medicine, American College of Medical Genetics, and US Environmental Protection Agency.

Presentation(s):

Send Email for Richard Sharp

Susanne B. Haga

Associate Professor
Duke University School of Medicine

Susanna Haga, PhD, is an Associate Professor at Duke University School of Medicine, Department of Population Health Sciences and the Center for Applied Genomics & Precision Medicine. She also has a secondary appointment in the Sanford School of Public Policy at Duke University and is a member of the Duke Center for Genomic and Computational Biology. Dr. Haga obtained her PhD in Human Genetics from the University of Maryland and has previously held positions in the Office of Biotechnology Activities at the National Institutes of Health and the Venter Institute. Her research interests focus on issues affecting the translation of genomics to clinical practice, particularly in the field of pharmacogenetic testing. She has a strong interest in education, with each of her research projects involving some component of professional, public or patient education, including development of educational materials about genomic research in general, clnical genetic testing, and communication of genetic test results, in addition to regularly teaching undergraduate courses, co-directing a post-doctoral program in genomic medicine, and mentoring students.

Presentation(s):

Send Email for Susanne Haga

Amy A. Lemke

Senior Research Scientist
NorthShore University HealthSystem

Amy Lemke, PhD, MS, is a senior research scientist in the Center for Personalized Medicine at NorthShore University HealthSystem. She also has a secondary appointment as a senior clinician researcher at the University of Chicago. Dr. Lemke received a Master of Science degree in genetic counseling from the University of California, Berkeley, and a PhD in Public Health, Community Health, from the University of Illinois at Chicago. She has collaborated on various NIH-funded projects exploring diverse stakeholder views on data sharing, privacy protections, return of research results, and other key issues in the management of genomic health information. Dr. Lemke is the principal investigator of patient and provider studies assessing the impact of pharmacogenomic testing in a community health system. Her current research examines implementation and outcomes of emerging genomic technologies and tests in personalized medicine.

Presentation(s):

Send Email for Amy Lemke


Assets

4B - Ethical Challenges in Pre-Emptive PGx Testing
CME (AMA PRA Category 1 Credits™) 1.5; ACPE (UAN: 0853-9999-17-062-L01-P) 1.5; CEU (NSGC Category 1) 0.15; Attendance CEU 1.5



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Ethical Challenges in Pre-Emptive PGx Testing
CME (AMA PRA Category 1 Credits™) 1.5; ACPE (UAN: 0853-9999-17-062-L01-P) 1.5; CEU (NSGC Category 1) 0.15; Attendance CEU 1.5